SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)

Omkar Panchal¹, Gunnar Wichmann², Reidar Grenman³, Lisa Eckhardt⁴, Leoni A. Kunz-Schughart⁴,⁵, Heike Franke⁶, Andreas Dietz² & Achim Aigner¹,⁷

Supplementary Information
Suppl. Materials and Methods

Radiosensitivity assay

In the radiosensitivity assays conditions were 8% CO₂ and humidified atmosphere. Media / supplements were from Biotech, Aidenbach, Germany. Cells were cultured only for two months which accounted for 12-16 passages, after which a new culture was thawed from the stock. Radioresponse was assessed in clonogenic survival assays. Single cell suspensions prepared from exponentially growing monolayer cultures pre-exposed for 72h to siLuc3 or siSATB1 in transfection reagent as described above were seeded into 6-well plates at defined densities (300 – 4,800 cells/well) in supplemented standard DMEM. After a 10 hours incubation interval to allow cell adherence, culture plates were irradiated at room temperature using single doses of 0-10 Gy with a dose-rate of about 1.3 Gy/min (200 kV X-rays; Yxlon Y.TU 320, Yxlon, 0.5 mm Cu filter). UT-SCC-42B and FaDu cells were then cultured for a total of 8 and 10 days, respectively, to guarantee ≥5 doublings and the formation of colonies consisting of ≥50 cells. Colonies were fixed and stained followed by manual microscopic counting to determine plating efficiencies (PEs). Survival fractions (SFs) relative to control conditions at 0 Gy were calculated and clonogenic survival curves were fitted, employing the linear-quadratic model $SF = e^{-(AD + BD^2)}$ (D: irradiation dose; A and B: variables defining the irradiation dose) as described in 1.

Clonogenic surviving fractions were statistically compared by independent Mann-Whitney-U tests including Bonferroni-Holm correction for multiple testing, while linear regression was used for statistical evaluation of the parameters A and B in the linear-quadratic functions modeling the irradiation dose dependent clonogenic survival curves. These tests were performed using SPSS Statistics 21 (IBM Corporation, NY) 1.

Western Blotting

For protein isolation, identical amounts of cells in suspension (500,000 cells, harvested by trypsinization and counted in a Neubauer chamber) were lysed or, if cell numbers in the wells were substantially different, the protein concentration of the total cell lysates (generated from cells in monolayer) was measured using the BioRad DC protein quantification kit (BioRad Laboratories, Munich, Germany). RIPA-SDS buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 1% (v/v) TritonX-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM EDTA, 10 mM NaF) was used for lysing the cells. Tumor homogenization was done with a tissue homogenizer (Ultra-turrax; IKA, Staufen, Germany). Cells in monolayer were scraped by cell scraper (Sarstedt; Nümbrecht, Germany) and cells in suspension were lysed only by pipetting. After homogenization (tumor/cell suspension/scraped cell lysate), undissolved cell debris was eliminated by centrifugation at 5,000 rpm for 10 min at 4 °C. For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 30 μg total protein was separated by SDS-PAGE, prior to transfer onto a 0.45 μm PROTRAN®
nitrocellulose membrane (Whatman, Dassel, Germany). Membranes were blocked with 5% (w/v) non-fat dry milk in TBST (10 mM Tris/HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20), washed with TBST and incubated overnight with primary antibodies at 4°C. For details on the specific antibodies used for immunodetection, see Suppl. Table 3. GAPDH or actin were used for loading control. After washing with TBST, membranes were incubated with horseradish peroxidase-coupled secondary antibodies conjugated with HRP for detection. Protein bands were visualized by using the chemiluminescence ECL kit from Thermo Fisher Scientific in a LAS-4000 chemiluminescence detection system (GE Healthcare, Munich, Germany). Immunoblots of SATB2 and its GAPDH loading controls were visualized using a secondary antibody conjugated with a NIR fluorophore. The detection was done in the near infrared region (700 and 800 nm) using an Odyssey Fc apparatus (LI-COR, Lincoln, NE). Densitometric analysis of Western blots was performed using ImageJ software, and expression levels were normalized to GAPDH.

**Immunofluorescence microscopy**

5,000 cells in 500 µl of complete medium were seeded per compartment on Superfrost excel slides (Thermo Fisher Scientific). Compartments for several independent samples were performed by using flexiPERM® reusable silicone inserts for compartmentalizing the growth surface (Sarstedt, Nümbrecht, Germany). 24 h after seeding, cells were transfected with 5 nM siRNA in 600 µl media as described above. Cells were fixed 96 h later with 100% ice cold methanol for 30 min at -20 °C. Antigen retrieval was done by boiling the slides for 10 min in 1x citrate buffer, pH 6.0 (Dako/Agilent, Santa Clara, CA), prior to washing in PBS. Unspecific binding was blocked by exposure to 5% (v/v) goat serum, 1% (w/v) BSA in PBS followed by incubating the slides with antibodies against SATB1 (EPR 3951, Abcam) at 4 °C overnight. In parallel, slides without primary antibody were run as negative control. After washing with PBS 3 times for 5 min, Cy3-labelled anti-rabbit antibodies (Jackson Immunoresearch, Ely, UK) were added and incubated at room temperature for 1 h, again followed by washing. To stain cell nuclei, the slides were incubated with 40 µg/ml Hoechst 33342 in TBS (Molecular Probes, Leiden, The Netherlands) for 10 min at room temperature. Images were taken with a confocal microscope (Leica SP8 confocal microscope; Leica, Wetzlar, Germany).

**Immunohistochemistry**

Tissues were fixed in 4% paraformaldehyde, prior to dehydration and paraffin embedding. Paraffin sections were fixed on the slide by baking at 56 °C overnight and microwaving for 5 min. For de-paraffination, slides were incubated 2 x 5 min in Neo-Clear (Merck, Darmstadt, Germany), followed by a series of decreasing ethanol concentrations (100%, 96%, 90%, 70%) and a final short washing step in distilled water. Antigen retrieval was done by microwave pre-treatment in 10mM sodium citrate buffer, pH 6.0, at 90 °C for 15 min. After cooling at room temperature for 10 min, slides were washed 2 x 5 min in PBST (PBS + 1% Tween-20). After washing 2 x 5 min in PBST, slides were
treated for 15 min at 4°C with 0.3% H$_2$O$_2$ in PBST, to block endogenous peroxidase activity. For blocking of nonspecific binding sites, slides were treated with blocking solution (PBST containing 2% bovine serum albumin, 10% normal serum from the secondary antibody source) at room temperature for 30 min, followed by incubation with the primary antibodies (mouse anti-Ki67 (1:100) or mouse anti-cleaved caspase-3 (1:50; see Suppl. Table 3 for details) in PBST/2% bovine serum albumin overnight at 4°C. After intensive washing in PBST, slides were incubated with a biotinylated anti-mouse or anti-rabbit secondary antibody (immunoglobulin IgG (H+L); 1:100; Vector Laboratories, Burlingame, CA) in PBST / 2% bovine serum albumin for 1 h at room temperature. For detection, slides were incubated with Avidin-Biotin complex solution (DAKO, Glostrup, Denmark) for 30 min at 37 °C. For visualization, slides were washed and then incubated in 1% 3,3’-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich) / H$_2$O$_2$ in PBST until the brown staining was observed under the microscope. Where applicable, sections were counterstained with hematoxylin, prior to dehydration in a series of graded ethanol, processing through n-butylacetate (Carl Roth, Karlsruhe, Germany) and coverslipping with Entellan (Merck). Control experiments were carried out without the primary antibody. Histoscores were derived from the blinded rating of the signal densities (Ki-67) or the total number of positive cells (cleaved caspase-3) in given percentages of the whole section, and are plotted as sum.

_SiRNA sequences_

Sequences were as follows: siSATB1 (‘467’) Sense: 5’- GCU UCA AGA UGU GUA UCA UdTdT-3’; antisense: 5’- AUG AUA CAC AUC UUG AAG CdTdT-3’; siSATB1 (‘989’) Sense: 5’- GUA UGC AGU GAA UAG ACU UdTdT -3’; antisense: 5’- AAG UCU AUU CAC UGC AUA CdTdT -3’; siLuc3 (serving as negative control); sense: 5’- CUU ACG CUG AGU ACU UCG AdTdT -3’, antisense: 5’- UCG AAG UAC UCA GCG UAA GdTdT -3’; siHER3: 5’- CCU UGA GAU UGU GCU CAC GTT -3’.

_Colony formation and spheroid assay_

For assessing the ability of the cells to form colonies on plastic, cells were trypsinized 72 h after transfection, counted as described above, and 1,000- 2,000 cells were seeded in a 6 well plate. Cells were allowed to grow for 5 – 8 days until each colony contained ~ 30 - 50 cells, prior to staining with 1% (w/v) methylene blue in 70% (v/v) ethanol solution for 45 to 60 min. Stained colonies were washed with distilled water, air dried, photographed and counted by image J.

For spheroid assays, transfected cells were trypsinized, counted, and 5,000 cells per well in 250 µl medium were seeded in Nexcelom 3D 96-well round bottom Ultra-low attachment plates (Nexcelom Bioscience, Lawrence, MA). Spheroids were allowed to grow for two weeks prior to taking photos. For live/dead stain, UT-SCC-14 spheroids were stained by adding 50 µl of complete media containing (total volume 300 µl) 5 µM Calcein AM (Thermo Fisher Scientific), 1 ng propidium iodide (Sigma-
Aldrich) and 6 ng Hoechst 33342 dye (Thermo Fisher Scientific). Images were recorded using a Celigo Imaging Cytometer (Nexcelom).

**Apoptosis assay**

Apoptosis was determined by detection of active Caspase 3/7 using a bioluminescent Caspase 3/7 Glo® assay (Promega, Mannheim, Germany). For this purpose, cells were seeded in 96 well plates at an initial density of 1,000 cells/well and transfected as described above. Detection of Caspase 3/7 activation was performed 72 h post transfection according to the manufacturer’s protocol. Luminescence was measured using a POLAR star Omega reader (BMG Labtec, Jena, Germany) after 1 h of incubation at room temperature in the dark. In parallel, cell numbers were determined using a WST-1 colorimetric assay (Roche, Mannheim, Germany), and used for the normalization of caspase luminescence results.

**Caspase inhibition assay**

Cells were seeded in a 96 well plate at density of 1000 or 2000 cells/well in 250 µl serum deficient media (2% FCS for UT-SCC-42B and 5% FCS for UT-SCC-15). Cells were transfected with 5 nM siRNA in 260 µl media, and caspase 3/7 inhibitor (Enzo Life Sciences, Lörrach, Germany; 20 µM or 25 µM for UT-SCC-42B or UT-SCC-15 cells, respectively) was added to the wells 24 h and 48 h post transfection. The number of viable cells was monitored at 72 h or 96 h post transfection by using the CCK8 reagent (Dojindo, Munich, Germany) and measuring the absorbance at 450 nm.

**Reference**

1. Hinrichs CN, Ingargiola M, Kaubler T, et al. Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization. *Molecular cancer therapeutics* 2018;17:393-406.
Suppl. Figure legends and Tables

**Suppl. Fig. 1. Determination of SATB1 and SATB2 expression levels in various cell lines.** (A) SATB2 mRNA levels. (B) SATB1 protein levels as determined by Western blotting (bars: quantitation normalized for GAPDH, lower panels: original Western blots). (C) Comparison of SATB1 expression levels in UT-SCC14 tumor xenografts vs. normal mucosa from tonsillitis patients (the asterisk denotes a sample with lower loading amounts due to limited tissue availability). (D) Scatter plot revealing the absence of a correlation between SATB1 and SATB2 mRNA levels. (E) SATB2 protein levels.

**Suppl. Fig. 2. Efficient siRNA-mediated SATB1 knockdown.** (A) Comparison of different SATB1-specific siRNAs (in the colon carcinoma cell line HCT-116; taken from 28,29). More details on the validation of efficacy and specificity of the si468 selected for subsequent experiments can be found in 28,29. (B) Profound reduction of SATB1 mRNA upon transfection with specific (siSATB1) vs. negative control (siCtrl) siRNAs or untreated cells. The comparison between various cell lines reveals that knockdown efficacies are independent of initial SATB1 expression levels. (C) Determination of SATB1 knockdown on the protein level. Original Western blots from three different cell lines at two different time points are shown, with GAPDH used as loading control. (D) Immunocytochemistry for analyzing SATB1 levels. Beyond the decrease in SATB1 expression upon siSATB1 transfection (lower panel) vs. negative control (siCtrl, upper panel), anti-proliferative effects are observed as well (scale bar: 100 µm). Knockdown is also observed in the higher magnification; see UT-SCC-14 cells as representative example, furthermore confirming the nuclear SATB1 localization (red; compare to blue Hoechst 33342 staining of siCtrl transfected cells; scale bar: 10 µm).

**Suppl. Fig. 3. Tumor cell-inhibitory effects upon SATB1 knockdown are dependent on the cell line, but not on initial SATB1 expression levels.** Cells after transient siRNA-mediated knockdown (siSATB1) are compared to negative control transfected (siCtrl) or untransfected cells. (A) Anchorage-dependent proliferation, (B) prolonged reduction of SATB1 protein levels upon siSATB1 transfection, as determined by Western blot; (C) colony formation on plastic (upper panel: quantitation; lower panel: original pictures of the corresponding wells; bar: 0.3 mm), (D) spheroid formation assay.

**Suppl. Fig. 4. Induction of apoptosis and effects on cell cycle upon SATB1 knockdown are dependent on the cell line.** (A) – (B) Caspase-3/-7 activities in two different cell lines as molecular readout downstream of both extrinsic and intrinsic apoptotic pathways.

**Suppl. Fig. 5. No alterations in cellular sensitivity towards radiation upon SATB1 knockdown.** (A) Reduced SATB1 levels upon siSATB1 transfection as compared to siCtrl lead to (B) inhibition of...
colony formation. (C) Cell survival upon radiation is strongly dependent on the dosage, but not affected by SATB1 knockdown.

Suppl. Fig. 6. SATB1 knockdown-mediated alterations in expression levels of HER3 and its ligands Heregulin A & B. (A) – (D) mRNA levels in four different cell lines. (E) – (F) Inhibitory effects of siRNA-mediated HER3 knockdown in two different cell lines. Lower panels: HER3 expression as determined by Western blot.

Suppl. Fig. 7. SATB1 knockdown-mediated alterations in expression levels of various genes. (A) – (B) mRNA levels of genes involved in EMT, cell cycle and cell viability.

Suppl. Table 1: Background information on cell lines used in this study

Suppl. Table 2. Sequences of primers used in this study

Suppl. Table 3: Background information on antibodies used in this study
A

UT-SCC-16B

Caspase activity (RLU)
norm. for cell density +/- SEM

B

UT-SCC-5

Caspase activity (RLU)
norm. for cell density +/- SEM

***

***
**Suppl. Figure 7**

**A**

**UT-SCC-42B**

![Graph showing mRNA levels with SEM for UT-SCC-42B with untreated, siSATB1, and siCtrl groups.](image)

**B**

**UT-SCC-16B**

![Graph showing mRNA levels with SEM for UT-SCC-16B with untreated, siSATB1, and siCtrl groups.](image)
| Primary cell culture | Sex | Age | Primary tumour location | TNM | Specimen site | Type of Lesion | Grade |
|----------------------|-----|-----|-------------------------|-----|---------------|----------------|-------|
| UT-SCC-5             | M   | 58  | Linguae                 | T1N1M0 | Tongue          | Primary         | G2    |
| UT-SCC-14            | M   | 25  | SCC linguae             | T3N1M0 | Tongue          | Primary         | G2    |
| UT-SCC-15            | M   | 51  | SCC linguae             | T1N0M0 | Tongue          | Recurrent       | G1    |
| UT-SCC-16A           | F   | 77  | SCC linguae             | T3N0M0 | Tongue          | Primary         | G3    |
| UT-SCC-16B           | F   | 77  | SCC linguae             | T3N0M0 | Neck            | Metastatic      | G3    |
| UT-SCC-19A           | M   | 44  | Glottic Larynx          | T4N0M0 | Larynx          | Primary         | G2    |
| UT-SCC-24A           | M   | 41  | SCC linguae             | T2N0M0 | Tongue          | Primary         | G2    |
| UT-SCC-26A           | M   | 60  | SCC hypopharynx         | T1N2M0 | Neck            | Metastatic      | G2    |
| UT-SCC-26B           | M   | 60  | SCC hypopharynx         | --    | Neck            | Metastatic      | G2    |
| UT-SCC-31            | M   | 58  | Floor of the mouth      | T3N2bM0 | Floor of the mouth | Primary | G1(G2) |
| UT-SCC-42A           | M   | 43  | Supraglottic Larynx     | T4N3M0 | Larynx          | Primary         | G3    |
| UT-SCC-42B           | M   | 43  | Supraglottic larynx     | T3N0M0 | Neck            | Primary         | G3    |
| UT-SCC-60A           | M   | 59  | Left tonsilla           | T4N1M0 | Tonsil (left)   | Primary         | G1    |
| UT-SCC-60B           | M   | 59  | Left tonsilla           | T4N1M0 | Neck            | Metastatic (per) | G1    |
| UT-SCC-62            | M   | 56  | Hypopharynx             | T4N0M0 | Neck            | Metastatic      | G2    |
| UT-SCC-74A           | M   | 31  | SCC linguae             | T3N1M0 | Tongue          | Primary         | G1-G2 |
| UT-SCC-74B           | M   |     | SCC linguae met colli   | rN2   | Neck            | Metastatic      | G2    |
| cDNA          | q-RT-PCR primers | Orientation | Sequence (5'-3')                  |
|--------------|------------------|-------------|-----------------------------------|
| SATB1        |                  | Forward     | CGA TGA ACT GAA ACG AGC AG        |
|              |                  | Reverse     | CGG AGG ATT TCT GAA AGC AA        |
| E-Cadherin   |                  | Forward     | GGC GGA GAA GAG GAC CAG GAC TT    |
|              |                  | Reverse     | CAT CGG GAT TGG CAG GGC GG        |
| N-Cadherin   |                  | Forward     | AAC TGG GCC AGG AGC TGA CCA       |
|              |                  | Reverse     | GTG CCC TCA AAT GAA ACC GGG CT    |
| Beta catenin |                  | Forward     | TCG AGG ACG GTC GGA CTC CC        |
|              |                  | Reverse     | CTG CCA GTG ACT AAC AGC CGC       |
| Cyclin B1    |                  | Forward     | CAT GGT GCA CT TCC TCC TT         |
|              |                  | Reverse     | AGG TAA TGT TGT AGA GTT GGT GTC  |
| Cyclin D1    |                  | Forward     | CCT CGG TGT CCT ACT TCA AA        |
|              |                  | Reverse     | CAC TTC TGT TCC TCG CAG A         |
| MMP7         |                  | Forward     | GGG GCA AAG AGA TCC CCC TGC AT    |
|              |                  | Reverse     | CCC CAT GAG CTC CTC GCG CAA A     |
| Pim-1        |                  | Forward     | ATC AGG GGC CAG GTT TT C T        |
|              |                  | Reverse     | GGG CCA AGC ACC ATC TAA T         |
| Survivin     |                  | Forward     | TGATGAGAGAGATGGAGACAGAGAG         |
|              |                  | Reverse     | ACAGCATGGCAAAAAGGAG               |
| MACC1        |                  | Forward     | TTC TTT TGA TTC CTC CGG TGA       |
|              |                  | Reverse     | ACT CTG ATG GGC ATG TG CTG        |
| HER1         |                  | Forward     | ACA CAG AAT CTA TAC CCA CCA GAG T |
|              |                  | Reverse     | ATC AAC TCCCAA ACG GTC AC         |
| HER2         |                  | Forward     | TGG CTC AGT GAC CTG TT T TG       |
|              |                  | Reverse     | GGT CCT TAT AGT GGG CAC AGG       |
| HER3         |                  | Forward     | CTG ATC ACC GGC CTC AAT           |
|              |                  | Reverse     | GGA AGA CAT TGA GCT TCT CTG G     |
| Heregulin A  |                  | Forward     | CCC ATG AAA GTC CAA AAC CA        |
|              |                  | Reverse     | CCG GTT ATG GTG AGC ACT CT         |
| Heregulin B  |                  | Forward     | GAT CAG CAA ATT AGG AAA TGA CA    |
|              |                  | Reverse     | GGC ATA CCA GTG ATG ATC TCG       |
Panchal et al., Suppl. Table 3: Background information on antibodies used in this study

| Method                  | Protein  | Clone/antibody | Dilution (Diluent)                          | Company                |
|-------------------------|----------|----------------|---------------------------------------------|------------------------|
| Western blot            | SATB1    | 14/SATB1       | 1:1000 (5% BSA in TBST)                     | BD bioscience          |
| Western blot            | SATB2    | ab92446        | 1:1000 (in Pierce blocking solution)        | Abcam                  |
| Western blot            | GAPDH    | ab 181602      | 1:10,000 (Pierce blocking solution)         | Abcam                  |
| Western blot            | Cyclin B1| ab32053        | 1:1000 (Pierce blocking solution)           | Abcam                  |
| Western blot            | HER3     | ab 32121       | 1:1000 (Pierce blocking solution)           | Abcam                  |
| Western blot            | Actin    | # 4970         | 1:2000 (Pierce blocking solution)           | Cell Signaling         |
| Western blot            | Anti-mouse| Product # 31430| 1:2000 (3% milk in TBST)                    | Thermo Fisher Scientific|
| Western blot            | Anti-rabbit| Ab 6721       | 1:5000 (3% milk in TBST)                    | Abcam                  |
| Western blot            | Anti-rabbit| 827-08365   | 1:10,000 (Pierce blocking solution)         | LI-COR                 |
| Western blot            | Anti-mouse| 926-68170     | 1:10,000 (Pierce blocking solution)         | LI-COR                 |
| Immunocytochemistry     | SATB1    | EPR 3951       | 1:200 (1% BSA in PBST)                      | Abcam                  |
| Immunocytochemistry     | Anti-rabbit (Cy3)| 111-165-144 | 1:800 (1% BSA in PBS)                      | Jackson Immuno-Research|
| Immunocytochemistry     | Hoechst 33342 | H1399     | 1:100 (PBST)                                | Invitrogen             |
| Immunohistochemistry    | Ki-67    | MIB-1          | 1:100 (2% BSA in PBST)                      | DAKO                   |
| Immunohistochemistry    | Cleaved caspase-3 | Rabbit polyclonal | 1:50 (2% BSA in PBST) | MBL International |